J 17 (Lamivudine 300 mg)
Pill imprint J 17 has been identified as Lamivudine 300 mg.
Lamivudine is used in the treatment of hepatitis b; hiv infection; occupational exposure; nonoccupational exposure and belongs to the drug class nucleoside reverse transcriptase inhibitors (NRTIs). Risk cannot be ruled out during pregnancy. Lamivudine 300 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Imprint:
- J 17
- Strength:
- 300 mg
- Color:
- White
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- Nucleoside reverse transcriptase inhibitors (NRTIs)
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Camber Pharmaceuticals, Inc.
More about lamivudine
Consumer resources
- Other brands: Epivir, Epivir-HBV
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
